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obese patients with T2DM. Cost-effectiveness (INR/unit of effective-
ness) varied from 3.7 to 45.2. Seventeen percent of the patients with 
T2DM included in this study received less cost-effective antidiabetic 
drugs.
Conclusions: Prescriptions of cost-effective antidiabetic drugs (83%) 
were more common than less cost-effective antidiabetic drugs (17%) 
in patients with T2DM from Mumbai, India.
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Background: Immunization is the most cost-effective intervention 
for infectious diseases, which are the major cause of morbidity and 
mortality worldwide. Vaccines not only protect the individual who 
is vaccinated but also reduce the burden of infectious vaccine-pre-
ventable diseases for the entire community.1 Adult vaccination is very 
important given that > 25% of mortality is due to infectious diseases.2 
There is a scarcity of information on the vaccination status of young 
adults and the role of socioeconomic conditions in India.
Objectives: The present study explored the adult vaccination status 
and influence of income and education of parents on adult vaccina-
tion status in university students from Mumbai, India.
Methods: This descriptive study was performed from January to 
April 2015 among undergraduate pharmacy students from Mumbai 
University, India, by using a validated study questionnaire. Students 
were contacted by a study team member in their classrooms and were 
given a brief introduction about the research project. Those who 
desired to participate in the study were explained the purpose and 
objectives of the study. On the basis of the eligibility criteria (those 
who gave written informed consent and were between the age group 
of 18–25 years), 149 students were selected for the present study. 
A total of 8 vaccines (namely, Tdap/DTP, varicella, measles-mumps-
rubella [MMR], influenza, pneumococcal, hepatitis A, hepatitis B, 
and meningococcal) were included in this study for all the respond-
ents. In addition to these vaccines, human papillomavirus (HPV) 
vaccine was also included for female respondents.
Results: There were total of 149 (75 males and 74 females) respond-
ents with a mean age of 21.5 years. The top 3 immunizations were 
Td/Tdap (97.3%), MMR (66.4%), and hepatitis B (55%) among the 
respondents. Only 4 (5.5%) female respondents had been immunized 
against HPV. The lowest income group (< 50,000 INR/month) had 
the least vaccination coverage for all the vaccines, except for MMR 
and HPV. Vaccination coverage was lesser for respondents with par-
ent’s education below a high school than those with parent’s edu-
cation of graduation and above, except for pneumococcal vaccine.
Conclusions: India’s National Centre for Disease Control has recom-
mended Td/Tdap, MMR, and varicella for all adults and influenza, 
pneumococci, hepatitis A, hepatitis B, meningococcal, and HPV for 
adults with certain risk factors. Td/Tdap (97.3%) and MMR (66.4%) 
coverage was in line with the recommendations. For all the other 
vaccines, the coverage was low, varying from 5.5% to 35.4%. The 
vaccination coverage was better in respondents with higher educated 
and higher income parents. We suggest that patient education, plan-
ning by government for the implementation of a policy for adult 
vaccination, and involvement of physicians are needed for better 
adult vaccination coverage.
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in defenSe of MedicAlly enhAncing huMAn 
MoRAlity
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Our species may plausibly boast that, in the relatively short period 
since it first emerged, it has enormously advanced in knowledge, 
science, and technical progress. When it comes to our moral develop-
ment, however, the distance we have covered is comparatively negligi-
ble. As a result, man today resembles a mighty giant who has no clue 
how to use his powers; and just like a child playing with grenades, 
man has become utterly dangerous to himself, to other species, and 
to the globe in general. The situation is bound to steadily deteriorate 
as long as the gap between our powers and our morality continues 
to increase. What if, however, we could medically accelerate our 
moral development? Even better, what if we could one and for all 
render our species totally immune to certain vices? The advances in 
biomedicine nowadays seem to hold such a promise. In this essay, 
I will discuss the prospect of medically intervening with the moral 
disposition of humans in such a way as to even eliminate morally 
unjustifiable choices. I will claim that such an intervention would 
not necessarily compromise either the free will or the autonomy of 
moral agents. To support my view, I will provide a set of arguments 
based on the Kantian tradition in ethics, since the opponents of moral 
enhancement mostly evoke arguments that focus on autonomy and 
free will. I will conclude with the view that moral enhancement by 
means of pharmaceutical intervention might even be a perfect duty 
for moral agents in the light of Kantian ethics.
Key words: autonomy, biomedicine, free will, Kantian ethics, moral 
enhancement, utilitarianism.
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Background: Many clinical trials, including those performed in the 
developing world, are designed and conducted by academics without 
pharmaceutical sponsorship, input, or supervision. Although many 
academics are adept at asking and answering basic scientific ques-
tions, unfortunately few academic institutions or investigators are 
equipped to provide the same quality of clinical trial design, conduct, 
and oversight as those done by the pharmaceutical industry.
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Methods: A review of academic clinical trials and documents dealing 
with the proper conduct of clinical trials was combined with both 
personal and published regulatory experience concerning the quality 
of data produced by academic clinical trials.
Results: Academic clinical trials often produce data that are not 
accepted by regulatory authorities for the approval or labeling of 
the treatments studied in the trials. Participants in such trials are 
therefore exposed to risks without producing any personal or societal 
benefits; by definition, such trials are unethical.
Conclusions: It is proposed that only clinical studies, including those 
done by academics, that are designed, conducted and monitored in 
such a way as to produce data suitable for regulatory approval should 
be funded, approved by institutional review boards/ethics commit-
tees, or conducted in the developed or developing world. Increased 
training of academic investigators, institutional review boards/ethics 
committees, as well as the public and private groups that fund clini-
cal trials, are needed to decrease the number of unethical academic 
clinical trials performed.
Key words: academic clinical trials, developing world, ethics, regula-
tory approval.
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Background: Proposal writing is a skill of fundamental importance 
to the researchers, and the proposal is an important step in develop-
ing a research project that gives an overview of it. It enables other 
people to understand the scope of the research and the significance 
of the research, as well as the proposed methodology and chosen 
research method. The purpose of this paper is to define the research 
proposal and review its importance and its different types. It also 
provides a generic outline that focuses on the components and sec-
tions of the research proposal and the basic format of each section.
Objectives: The main objectives are to highlight the importance of 
writing a research proposal. It also aims to define the research and 
its different types as well as to identify the components and sections 
of a research proposal and to explain the content of each section.
Methods: A comprehensive literature review on research proposal writ-
ing has been conducted by using academic databases and some search 
engines. The focus was on the general format, guidelines, and presenta-
tion that suit students and scholars in different disciplines of life sciences. 
Various sections of a research proposal are discussed in detail. The focus 
is to motivate young researchers to take up challenging problems.
Results: The basic definitions of research and proposal in general and 
in health in particular were given and explained. Useful guidelines 
for the identification and selection of a research topic were also dis-
cussed in detail. The questions relating to whether a research problem 
is adequately analyzed and whether it is clearly stated were also 
addressed. Development of research objectives and literature reviews 
were also discussed. A special emphasis was given to elements of the 
“Methods” section of a research proposal, as well as the development 
of a work plan, and the preparation of a budget was highlighted.
Key words: proposal, research, research health system, research 
methodology.
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Background: Ever since the 1996 revision of the Declaration of 
Helsinki, the World Medical Association has attempted to address 
ethical and scientific concerns of its diverse stakeholders for Articles 
33 (use of placebo) and 34 (posttrial provisions), most recently in 
2013. Both are inextricably linked to standard of care, an essential 
element of any comparative, interventional clinical trial. But has 
this now 20-year-long ethical debate truly been put to rest? The 
choice of standard of care in clinical trials remains a complex issue, 
particularly for comparative trials conducted in emerging countries. 
Interpretations of the Declaration of Helsinki as the cornerstone 
document for medical ethics range from best intervention available 
worldwide to any locally available standard of care for the compara-
tor group, which in the worst case could mean no interventional 
care at all.1,2
Objectives: Our aim was to examine the current status of clinical 
research practice and ethical guidance on standard of care, with a 
focus on international health research, and to review corresponding 
guidance issued by pharmaceutical sponsors in their publicly acces-
sible policies on clinical research.
Methods: We reviewed ethical recommendations before and after 
2013 and scientific literature, as well as major clinical trial registries 
(European Union, United States, and World Health Organization), 
to assess current clinical research practice related to standard of 
care. Furthermore, the websites of the top-ranked 25 pharmaceuti-
cal companies on sales figures in 20143 were reviewed for publicly 
accessible policies with reference to standard of care in clinical trials 
in emerging regions.
Results: After a period of active scientific-ethical debate before the 
2013 revision of the Declaration of Helsinki, few ethical discussions 
or recommendations have since been published that could provide 
additional guidance to clinical researchers. The recent scientific lit-
erature reflects the continued challenge for researchers to design 
an ethically and scientifically sound study, especially in vulnerable 
populations. However, ~20% of registered open clinical trials across 
major trial registries are designed with a placebo control, suggest-
ing that the question of standard of care remains highly pertinent. 
The review of pharmaceutical sponsor websites revealed a highly 
variable picture with regard to publicly available policies or state-
ments on this issue, particularly for research conducted in low- to 
middle-income countries. The review outcome spans results from 
any policy published to very clearly worded statements on clinical 
research in developing countries, the standard of care aspect dur-
ing the trial conduct, and regulatory strategies after completion of 
product development.
Conclusions: Investigators, ethics committees, and sponsors continue 
to be confronted with the challenge of ensuring ethically and scien-
tifically sound clinical studies with appropriate standard of care. We 
have attempted to examine available ethical guidance and summarize 
recommendations for clinical trial designs that could assist in address-
ing these challenges. Care should be taken to maintain a high level 
of awareness for the importance of a sound ethical framework for a 
scientifically valid clinical trial design. Pharmaceutical companies, as 
major sponsors of clinical research, should demonstrate awareness and 
an appropriate management of these aspects, particularly in regions 
with limited resources. As part of the ongoing debate on transparency, 
one option could be to formulate positions and make them available to 
the public, regardless of whether such a statement is legally required. 
A few examples already exist where such clarifying statements have 
been provided. This approach would prepare the ground for an open 
and transparent communication to agencies, ethics committee, and, 
last but not least, patients.
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